Genetic Roadmap Overcomes Tumor Heterogeneity to Advance Precision Oncology for Liver Cancer

BGI Genomics develops a 1,341-gene signature to classify iCCA liver cancer subtypes, overcoming biopsy bias to enable targeted precision oncology.

By: AXL Media

Published: Mar 31, 2026, 8:47 AM EDT

Source: Information for this report was sourced from BGI Genomics.

Navigating the Molecular Complexity of Secondary Liver Malignancies

Intrahepatic cholangiocarcinoma (iCCA) represents the second most common primary liver cancer, yet it remains notoriously difficult to treat due to its high level of intratumoral heterogeneity. Traditional biopsies often fail to provide a complete biological picture because different regions of the same tumor can display vastly different molecular characteristics. Research indicates that standard classification methods misidentify over 25% of tumors and up to 66% of immune profiles depending on where the sample is taken. To solve this, researchers from BGI Genomics and Fudan University have established a navigational framework that filters out genetic "noise" to focus on stable markers, providing a more robust foundation for clinical diagnosis.

The LIHV Gene Signature as a Tool Against Sampling Bias

The core of this new "roadmap" is the Low-Intratumor Heterogeneity/High-Intertumor Variability (LIHV) gene set. This 1,341-gene signature prioritizes markers that remain consistent throughout an individual’s tumor but vary significantly between different patients. By focusing on these stable indicators, the framework allows small biopsy samples to accurately represent the entire malignancy, regardless of the sampling site. This methodological shift enables a reproducible classification of iCCA into five subtypes, each with its own clinical prognosis and specific genetic mutations, such as KRAS, IDH1/2, and BAP1.

Subtype Classification and Associated Clinical Outcomes

The research categorizes iCCA into three primary groups, further divided into five subtypes. The Inflammatory subtype (SI) is linked to the most aggressive disease and the poorest prognosis, often characterized by strong neutrophil infiltration and high serum markers. In contrast, the SIII group—which includes atypical, immune-silent, and neurodegenerative subtypes—is generally associated with small bile duct-type iCCA and yields significantly better clinical outcomes. The Metabolic subtype (SII) presents a unique profile with the highest tumor mutation burden, suggesting that while the phenotype is immunosuppressive, it may be particularly responsive to specific checkpoint inhibitors.